These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 8113848)
1. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. Mitchell MS; Jakowatz J; Harel W; Dean G; Stevenson L; Boswell WD; Groshen S J Clin Oncol; 1994 Feb; 12(2):402-11. PubMed ID: 8113848 [TBL] [Abstract][Full Text] [Related]
2. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813 [TBL] [Abstract][Full Text] [Related]
3. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Mitchell MS Semin Oncol; 1998 Dec; 25(6):623-35. PubMed ID: 9865677 [TBL] [Abstract][Full Text] [Related]
4. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Vaishampayan U; Abrams J; Darrah D; Jones V; Mitchell MS Clin Cancer Res; 2002 Dec; 8(12):3696-701. PubMed ID: 12473578 [TBL] [Abstract][Full Text] [Related]
5. Active-specific immunotherapy for melanoma. Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701 [TBL] [Abstract][Full Text] [Related]
6. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H; Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809 [TBL] [Abstract][Full Text] [Related]
7. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. Kirkwood JM; Strawderman MH; Ernstoff MS; Smith TJ; Borden EC; Blum RH J Clin Oncol; 1996 Jan; 14(1):7-17. PubMed ID: 8558223 [TBL] [Abstract][Full Text] [Related]
8. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer. Iversen TZ Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457 [TBL] [Abstract][Full Text] [Related]
9. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Elliott GT; McLeod RA; Perez J; Von Eschen KB Semin Surg Oncol; 1993; 9(3):264-72. PubMed ID: 8516615 [TBL] [Abstract][Full Text] [Related]
10. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Mitchell MS; Harel W; Kan-Mitchell J; LeMay LG; Goedegebuure P; Huang XQ; Hofman F; Groshen S Ann N Y Acad Sci; 1993 Aug; 690():153-66. PubMed ID: 8368734 [TBL] [Abstract][Full Text] [Related]
11. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. Khayat D; Borel C; Tourani JM; Benhammouda A; Antoine E; Rixe O; Vuillemin E; Bazex PA; Thill L; Franks R J Clin Oncol; 1993 Nov; 11(11):2173-80. PubMed ID: 8229131 [TBL] [Abstract][Full Text] [Related]
12. Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine. Mitchell MS; Liggett PE; Green RL; Kan-Mitchell J; Murphree AL; Dean G; Spears L; Walonker F J Clin Oncol; 1994 Feb; 12(2):396-401. PubMed ID: 8113847 [TBL] [Abstract][Full Text] [Related]
14. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. Sparano JA; Fisher RI; Sunderland M; Margolin K; Ernest ML; Sznol M; Atkins MB; Dutcher JP; Micetich KC; Weiss GR J Clin Oncol; 1993 Oct; 11(10):1969-77. PubMed ID: 8410122 [TBL] [Abstract][Full Text] [Related]
15. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. Cole BF; Gelber RD; Kirkwood JM; Goldhirsch A; Barylak E; Borden E J Clin Oncol; 1996 Oct; 14(10):2666-73. PubMed ID: 8874325 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Lane AM; Egan KM; Harmon D; Holbrook A; Munzenrider JE; Gragoudas ES Ophthalmology; 2009 Nov; 116(11):2206-12. PubMed ID: 19744725 [TBL] [Abstract][Full Text] [Related]
18. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. Marincola FM; White DE; Wise AP; Rosenberg SA J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617 [TBL] [Abstract][Full Text] [Related]
19. Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies. Kirkwood JM Eur J Cancer; 1998 Jul; 34 Suppl 3():S12-7. PubMed ID: 9849403 [TBL] [Abstract][Full Text] [Related]
20. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]